EverSource Wealth Advisors’s Eikon Therapeutics EIKN Stock Holding History

EverSource Wealth Advisors’s Portfolio EIKN Stock Details EIKN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$763	Buy	+95	New	+$956	﹤0.01%	4058

Other funds holding EIKN

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Merck & Co Rahway, New Jersey $820M AUM 395.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Regents of the University of California Oakland, California $6.64B AUM 23.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

SCM

Soros Capital Management New York $182M AUM 108.83% 1-Year Est. Return

Walleye Capital New York $109B AUM 29.28% 1-Year Est. Return

EverSource Wealth Advisors's EIKN Position: Q3 2026 in Review

EverSource Wealth Advisors opened a new position in Eikon Therapeutics (EIKN) in Q3 2026: 95 shares worth $763. The stake represents ﹤0.01% of the portfolio and ranks #4058 among its holdings.

63 funds tracked by Wall St. Rank hold EIKN as of Q3 2026.

EverSource Wealth Advisors held 95 shares of Eikon Therapeutics worth $763 as of Q3 2026.
Eikon Therapeutics was a new EverSource Wealth Advisors position in Q3 2026.
Eikon Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q3 2026, its #4058 holding.
63 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q3 2026.

Based on EverSource Wealth Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.